Navigation Links
Study points to cocktail therapy for Alzheimer's
Date:7/8/2008

CAMBRIDGE, Mass. -- A dietary cocktail that includes a type of omega-3 fatty acid can improve memory and learning in gerbils, according to the latest study from MIT researchers that points to a possible beverage-based treatment for Alzheimer's and other brain diseases.

The combination of supplements, which contains three compounds normally found in the bloodstream, is now being tested in Alzheimer's patients. The cocktail has previously been shown to promote growth of new brain connections in rodents.

"It may be possible to use this treatment to partially restore brain function in people with diseases that decrease the number of brain neurons, including, for example, Alzheimer's disease, Parkinson's, strokes and brain injuries. Of course, such speculations have to be tested in double-blind, placebo-controlled clinical trials," said Richard Wurtman, Cecil H. Green Distinguished Professor of Neuropharmacology and senior author of a paper on the new work.

Such trials are now underway in Europe. A paper describing preliminary results has been submitted to the Alzheimer's Association International Conference on Alzheimer's Disease, to be held in Chicago July 26-31.

The new findings in gerbils appeared in the July 7 online edition of the Journal of FASEB (Federation of American Societies of Experimental Biology).

The researchers found that normal gerbils treated with the mixturea combination of DHA (a type of omega-3 fatty acid), uridine and cholineperformed significantly better on learning and memory tests than untreated gerbils.

Wurtman developed the treatment as a new approach to tackling Alzheimer'srestoring the synapses, or connections between brain cells, that leads to cognitive decline in Alzheimer's patients.

Synapses, where information is passed between neurons, play a critical role in learning and memory. Wurtman's laboratory has previously shown that the cocktail treatment improves those functions in rats with cognitive impairments.

The three dietary supplements under investigation are precursors to the fatty molecules that make up cell membranes, including the membranes of brain cells, which form synapses.

In the FASEB study, Wurtman and his colleagues found that gerbils that received all three supplements had up to 70 percent more phosphatides (a type of molecule that forms cell membranes) than control mice, suggesting that new synapses are forming.

"The improvements in cognition observed in normal gerbils in this study and in rats with impaired cognition, in a previous study, correlate perfectly with the evidence of increased brain synapses, as shown biochemically and anatomically," said Wurtman. "This suggests that treating the animals with the experimental mixture affects behavior by increasing the number of synapses in important brain regions.

Some of the gerbils in the studies received all three compounds and some received only two. The improvements in apparent synapse growth and cognitive ability were greatest in the rats given all three.

Omega-3 fatty acids are not produced in the body but are found in a variety of sources, including fish, eggs, flaxseed and meat from grass-fed animals. Choline can be synthesized in the body and obtained through the diet; it is found in meats, nuts and eggs. Uridine cannot be obtained from food sources, but is a component of human breast milk and can be produced in the body.


'/>"/>

Contact: Teresa Herbert
therbert@mit.edu
617-258-5403
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications
2. AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing
3. Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss
4. Kaiser Permanente study finds keeping a food diary doubles diet weight loss
5. Overweight, insulin resistant women at greater risk of advanced breast cancer diagnosis, says study
6. US firms a role model for fair hiring standards, study says
7. St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease
8. 98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study
9. 98 percent of elective mastectomy patients would have reconstruction again, says ASPS study
10. MDS Pharma Services Launches Next Generation Phase I Study Management System
11. Geisinger study: PTSD causes early death from heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: